Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Should You Sell?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares gapped down before the market opened on Monday . The stock had previously closed at $9.44, but opened at $8.84. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.90, with a volume of 66,592 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SGIOY shares. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has an average rating of “Hold”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.6%

The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average price is $10.11 and its 200-day moving average price is $9.88. The stock has a market cap of $15.05 billion, a price-to-earnings ratio of 11.05, a P/E/G ratio of 3.41 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The company had revenue of $881.71 million for the quarter, compared to the consensus estimate of $895.52 million. On average, sell-side analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.